Talk Bio

Roche has signed an exclusive global licensing agreement with Simcere Zaiming for SIM0660, a trispecific T-cell engager targeting CD79a, CD19, and CD3. Simcere will receive $75 million upfront and may receive up to approximately $1.53 billion in total payments, including development and commercial milestones, plus tiered royalties reaching the double-digit range on future net sales. SIM0660 is intended primarily for B-cell malignancies, including newly diagnosed and relapsed/refractory B-cell lymphoma. Its broader potential could extend to other B-cell-mediated diseases, such as autoimmune disorders, although Roche’s current focus is oncology. The molecule is an early-stage asset: reports differ on whether it is described as preclinical or in early clinical testing, so its safety and efficacy remain unproven. The agreement marks another major China-originated licensing deal for Roche and adds to Simcere’s growing out-licensing track record. It follows Simcere’s earlier, rough...